Table IIA.

Hematopoietic stem cell transplantation procedure and outcome

Patient	Age at HSCT (years)	Pre-treatment	Conditioning regimen	Bu AUC (mg* h/L)	GVHD prophylaxis	Donor type	Donor cell source	Cell dose (×106 CD34+ cells/kg)	Day of neutrophil engraftment	Complications	GVHD	Chimerism at last measurement (years post-HSCT)	Status (years post-HSCT)
1	3.2	Rituximab for EBV viremia	Bu/Cy	67.2	CSA/MTX	MSD	BM	16.57	31		-	T cell: >97% B cell: >97% Myeloid: >95% (3.2)	A&W (4.6)
2	8.9		Bu/Cy	67.1	CSA/MTX	MSD	BM	9.39	18	Klebsiella sepsis	-	T cell: 100% B cell: 97% Myeloid: 100% (0.1)	Patient deceased at day +58
3	10.2	Rituximab for EBV viremia	Bu/Flu	77.3	CSA/MTX	MSD	BM	11.75	27	CMV reactivation; persistent and worsening CNS white matter changes (leukoencephalopathy) and neurologic symptoms responsive to corticosteroids; idiopathic pneumonia syndrome (day +91) treated with etanercept	-	T cell: >97% B cell: >97% Myeloid: >97% (2.5)	A&W (4.2) Otitis treated with tympanostomy tubes
4	11.0	Living related liver transplant for liver failure/chronic sclerosing cholangitis	Bu/Flu	90.5	Tacrolimus/MTX	MSD	BM	13.49	28	Neurologic symptoms of unclear etiology, pericardial effusion, presumed viral meningoencephalitis responsive to Foscarnet	-	T cell: >97% B cell: >97% Myeloid: >97% (2.7)	A&W (3.7). Pneumonias, asymptomatic EBV viremia
5	5.8		Bu/Flu	70.8	CSA/MTX	MSD	BM	10.38	20		-	T cell: 96% B cell: >97% Myeloid: >97% (0.6)	A&W (2.0)
6	7.0	Lung resections x 2	Bu/Flu	87.8	CSA/MTX	MSD	BM	12.75	27	Disseminated HSV with Bell’s palsy	-	T cell: >97% B cell: >97% Myeloid: >97% (2.3)	A&W (2.5) Pneumonias, otitis treated with tympanostomy tubes, abscesses
7	8.0	Rituximab for EBV viremia; resection of leiomyosarcoma	Bu/Flu/rATG	50.1	CSA/MTX	MSD	BM	6.26	29	CMV pneumonitis, EBV viremia, transient pseudotumor cerebri	No acute	T cell: 100% B cell: 100% Myeloid: 100% (0.5)	A&W (0.6)